NEW YORK – Roswell Park Comprehensive Cancer Center is working with Generate:Biomedicines to discover and develop CAR T-cell therapies and armoring technologies for up to three oncology targets, including ovarian and other solid tumors.
In the collaboration announced Wednesday, Generate will use its machine learning-driven platform to help Roswell Park design, develop, and manufacture cell therapies. Roswell Park will be responsible for leading Phase I and II clinical trials on cell therapies produced with Generate's platform. Generate and Roswell Park will share R&D expenses as well as profits from any cell therapy products that advance to the market.
Somerville, Massachusetts-based Generate aims to determine the general rules by which a linear amino acid sequence encodes protein structure and function by training its algorithms on all known protein sequences and structures found in nature, as well as on experimental data. Then, using those rules, it will create new protein-based drugs on demand with specific therapeutic functions.
In April, the company partnered with MD Anderson Cancer Center to jointly discover and develop protein therapeutics for up to five oncology targets in advanced cancer, including small cell and non-small cell lung cancer. Generate also inked a discovery collaboration with Amgen in January 2022 around five clinical targets. Under that agreement, Amgen paid Generate $50 million upfront and could pay an additional $370 million in future milestone payments and up to low-double-digit royalties.
Generate and Roswell Park didn't disclose the financial terms of their agreement.